BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1767 related articles for article (PubMed ID: 24581995)

  • 21. [Local recurrence and survival rate after rectal cancer operations and multimodal therapy].
    Thomschke D; Kyau-Ummen B; Halbfass HJ
    Chirurg; 2002 Mar; 73(3):245-54. PubMed ID: 11963499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
    Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis.
    Sung S; Kim SH; Lee JH; Nam TK; Jeong S; Jang HS; Song JH; Lee JW; Bae JM; Lee JH
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):647-653. PubMed ID: 28581407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transanal Endoscopic Microsurgery (TEM) Following Neoadjuvant Chemoradiation for Rectal Cancer: Outcomes of Salvage Resection for Local Recurrence.
    Perez RO; Habr-Gama A; São Julião GP; Proscurshim I; Fernandez LM; de Azevedo RU; Vailati BB; Fernandes FA; Gama-Rodrigues J
    Ann Surg Oncol; 2016 Apr; 23(4):1143-8. PubMed ID: 26577119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
    Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
    Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
    Sprenger T; Rothe H; Becker H; Beissbarth T; Homayounfar K; Gauss K; Kitz J; Wolff H; Scheel AH; Ghadimi M; Rödel C; Conradi LC; Liersch T
    Am J Surg Pathol; 2013 Aug; 37(8):1283-9. PubMed ID: 23851331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circumferential resection margin involvement after laparoscopic abdominoperineal excision for rectal cancer.
    Raftopoulos I; Reed JF; Bergamaschi R
    Colorectal Dis; 2012 Apr; 14(4):431-7. PubMed ID: 21689315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suboptimal surgery and omission of neoadjuvant therapy for upper rectal cancer is associated with a high risk of local recurrence.
    Bondeven P; Laurberg S; Hagemann-Madsen RH; Ginnerup Pedersen B
    Colorectal Dis; 2015 Mar; 17(3):216-24. PubMed ID: 25510260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study.
    Madbouly KM; Abbas KS; Hussein AM
    Am J Surg; 2014 Jun; 207(6):824-31. PubMed ID: 24112666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
    Lin Y; Lin H; Xu Z; Zhou S; Chi P
    J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
    Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
    Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
    Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
    Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
    Selvindos PB; Ho YH
    Dis Colon Rectum; 2008 Nov; 51(11):1710-1. PubMed ID: 18679748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?
    Rahbari NN; Ulrich AB; Bruckner T; Münter M; Nickles A; Contin P; Löffler T; Reissfelder C; Koch M; Büchler MW; Weitz J
    Ann Surg; 2011 Mar; 253(3):522-33. PubMed ID: 21209587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.
    Marinello FG; Frasson M; Baguena G; Flor-Lorente B; Cervantes A; Roselló S; Espí A; García-Granero E
    Dis Colon Rectum; 2015 Jun; 58(6):556-65. PubMed ID: 25944427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study.
    Strassburg J; Ruppert R; Ptok H; Maurer C; Junginger T; Merkel S; Hermanek P
    Ann Surg Oncol; 2011 Oct; 18(10):2790-9. PubMed ID: 21509631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
    Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
    Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term oncologic results in cancer of the rectum treated by preoperative chemoradiotherapy and surgery: An analysis of 500 cases.
    Cienfuegos JA; Baixauli J; Pastor C; Arredondo J; Sola JJ; Arbea L; Chopitea A; Hernández-Lizoáin JL
    Rev Esp Enferm Dig; 2015 Jun; 107(6):340-6. PubMed ID: 26031861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 89.